Shenzhen Neptunus Bioengineering Co Documents
Documents
0
Ticker
000078.SZ
ISIN
CNE000000X95
Shenzhen Neptunus Bioengineering Co SEC Filings
Type | Report | Date |
|---|---|---|
| No documents available | ||
Shenzhen Neptunus Bioengineering Co Documents 2026
This page contains all official documents and SEC filings for Shenzhen Neptunus Bioengineering Co stock (000078.SZ, ISIN: CNE000000X95). This includes annual reports (Form 10-K), quarterly reports (Form 10-Q), and insider transactions (Form 4). Currently 0 documents are available. Data is updated regularly to provide investors with a complete overview of Shenzhen Neptunus Bioengineering Co's regulatory filings.
Shenzhen Neptunus Bioengineering Co Stock analysis
Shenzhen Neptunus Bioengineering Co Shenzhen Neptunus Bioengineering Co., Ltd. generates revenue through its pharmaceutical products and healthcare offerings. The company produces anti-tumor products, cardiovascular drugs, marine drugs, respiratory drugs, anti-infective products, and other pharmaceuticals. It also sells healthcare products, health food, and medical instruments. The primary market for these products is the domestic market, with East China being the main regional focus. The company serves healthcare providers, hospitals, and consumers within China's pharmaceutical sector. Neptunus targets the Chinese domestic market, emphasizing East China as its core region. Its product portfolio spans multiple therapeutic areas including oncology, cardiology, respiratory care, and infection control. The company's distribution network focuses on reaching hospitals and healthcare facilities across China, particularly in the East China region. The firm's health food and medical instrument lines complement its pharmaceutical business, creating diversified revenue streams within the healthcare industry. The business model relies on selling established pharmaceutical products alongside healthcare and medical solutions. Anti-tumor products and cardiovascular drugs form key segments of its revenue, supported by marine drugs and respiratory medications. East China's dominance in sales reflects the company's strategic market focus. The company's full-time employee count of 9,874 supports its manufacturing and distribution operations across China's domestic market.